Article from The New York Times features comments from OSU College of Pharmacy’s Dr. Daniel Hartung
“Trump Officials Say Drug Prices Are Inflated. So Are Some of Their Claims on a Solution.”
“In his zeal to fulfill a campaign promise, President Trump has correctly identified high drug prices as a major problem for many Americans. But in defending his proposed solutions, he has sometimes stretched the facts…”
“…The new pricing model, unveiled less than two months ago, has encountered a torrent of criticism from drug companies, which benefit from high prices under the current system, and from conservative groups, which accuse Mr. Trump of trying to import price controls from foreign countries….”
“…Most of the 36 countries in the Organization for Economic Cooperation and Development ‘regulate pharmaceutical prices directly or indirectly through coverage determinations,’ the group said in a report last month….”
“Daniel Hartung, an associate professor at the Oregon State University College of Pharmacy, explained: ‘Many O.E.C.D. countries have single-payer systems in which the government is essentially setting prices and telling companies what it will pay for coverage. That’s how they can extract substantial reductions relative to prices paid in the United States.'”
Click here to read the full version of this article by Robert Pear of The New York Times.